Low levels of tumour suppressor miR-655 in plasma contribute to lymphatic progression and poor outcomes in oesophageal squamous cell carcinoma
Low levels of tumour suppressor miR-655 in plasma contribute to lymphatic progression and poor outcomes in oesophageal squamous cell carcinoma
复制标题
DOI：
10.1186/s12943-018-0929-3
复制
发表时间：
2019-01-04
期刊：
影响因子：
37.3
通讯作者：
Otsuji, Eigo
中科院分区：
文献类型：
--
作者：
Kiuchi, Jun;Komatsu, Shuhei;Otsuji, Eigo
最近的研究发现，血浆/血清中低水平的肿瘤抑制微RNA（miRNA）与肿瘤进展和癌症预后不良有关。我们通过NCBI数据库的系统回顾，筛选出6个候选的食管鳞状细胞癌（oesophageal squamous cell carcinoma，ESCC）肿瘤抑制miRNAs（miR-126，133 b，143，203，338- 3 p，655）。其中，通过测试和验证规模分析，与健康志愿者相比，ESCC患者血浆中的miR-655水平显著下调。血浆中低水平的miR-655与淋巴管浸润、淋巴结转移和晚期显著相关。单因素和多因素分析显示，血浆miR-655水平低是淋巴结进展的独立危险因素，也是不良预后因素。miR-655在食管鳞癌细胞中的过表达抑制了细胞的增殖、迁移、侵袭和上皮间质转化。通过皮下注射增加血浆miR-655水平显著抑制小鼠中的淋巴结转移。血浆中低水平的miR-655与淋巴进展和不良结局相关，血浆miR-655水平的恢复可能抑制ESCC中的肿瘤和淋巴进展。
Recent studies identified that low levels of tumour suppressor microRNAs (miRNAs) in plasma/serum relate to tumour progression and poor outcomes in cancers. We selected six candidates (miR-126, 133b, 143, 203, 338-3p, 655) of tumour suppressor miRNAs in oesophageal squamous cell carcinoma (ESCC) by a systematic review of NCBI database. Of these, miR-655 levels were significantly down-regulated in plasma of ESCC patients compared to healthy volunteers by test- and validation-scale analyses. Low levels of plasma miR-655 were significantly associated with lymphatic invasion, lymph node metastasis and advanced stage. Univariate and multivariate analysis revealed that the low level of plasma miR-655 was an independent risk factor of lymphatic progression and a poor prognostic factor. Overexpression of miR-655 in ESCC cells inhibited cell proliferation, migration, invasion and epithelial-mesenchymal transition. Increased plasma miR-655 levels by the subcutaneous injection significantly inhibited lymph node metastasis in mice. Low levels of miR-655 in plasma relate to lymphatic progression and poor outcomes, and the restoration of the plasma miR-655 levels might inhibit tumour and lymphatic progression in ESCC.